Abstract
The oncogenic transcription inhibitor lurbinectedin (ZEPZELCA (TM)) is being developed by PharmaMar as a treatment for various cancers. The drug has b......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
